Neuroendocrine Responses to Physostigmine in Alzheimer's Disease

Murray A. Raskind, Elaine R. Peskind, Richard C. Veith, Steven C. Risse, Thomas H. Lampe, Soo Borson, Gail Gumbrecht, Daniel Dorsa

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

To assess central nervous system cholinergic neuroendocrine regulation in Alzheimer's disease (AD), we measured plasma arginine vasopressin, β-endorphin, and epinephrine responses to a cholinergic challenge elicited by intravenous administration of the acetylcholinesterase inhibitor physostigmine (0.0125 mg/kg) in male patients with AD (n =12) and compared their responses with those of age-matched normal control subjects (n =12). Physostigmine promptly increased plasma arginine vasopressin (tenfold), β-endorphin (twofold to threefold) and epinephrine (threefold) levels in elderly control subjects. In contrast, patients with AD showed attenuated responses to physostigmine. When controls and patients with AD who experienced nausea (n = 2 and n = 6, respectively) were excluded, the arginine vasopressin, β-endorphin, and epinephrine responses of patients with AD were significantly less than those of control subjects. These data suggest that the central nervous system cholinergic deterioration of AD results in decreased responsiveness of neuroendocrine systems that are regulated by central cholinergic mechanisms.

Original languageEnglish (US)
Pages (from-to)535-540
Number of pages6
JournalArchives of General Psychiatry
Volume46
Issue number6
DOIs
StatePublished - 1989
Externally publishedYes

Fingerprint

Physostigmine
Alzheimer Disease
Endorphins
Cholinergic Agents
Arginine Vasopressin
Epinephrine
Central Nervous System
Neurosecretory Systems
Cholinesterase Inhibitors
Intravenous Administration
Nausea
Alzheimer's Disease

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Psychiatry and Mental health

Cite this

Raskind, M. A., Peskind, E. R., Veith, R. C., Risse, S. C., Lampe, T. H., Borson, S., ... Dorsa, D. (1989). Neuroendocrine Responses to Physostigmine in Alzheimer's Disease. Archives of General Psychiatry, 46(6), 535-540. https://doi.org/10.1001/archpsyc.1989.01810060057009

Neuroendocrine Responses to Physostigmine in Alzheimer's Disease. / Raskind, Murray A.; Peskind, Elaine R.; Veith, Richard C.; Risse, Steven C.; Lampe, Thomas H.; Borson, Soo; Gumbrecht, Gail; Dorsa, Daniel.

In: Archives of General Psychiatry, Vol. 46, No. 6, 1989, p. 535-540.

Research output: Contribution to journalArticle

Raskind, MA, Peskind, ER, Veith, RC, Risse, SC, Lampe, TH, Borson, S, Gumbrecht, G & Dorsa, D 1989, 'Neuroendocrine Responses to Physostigmine in Alzheimer's Disease', Archives of General Psychiatry, vol. 46, no. 6, pp. 535-540. https://doi.org/10.1001/archpsyc.1989.01810060057009
Raskind, Murray A. ; Peskind, Elaine R. ; Veith, Richard C. ; Risse, Steven C. ; Lampe, Thomas H. ; Borson, Soo ; Gumbrecht, Gail ; Dorsa, Daniel. / Neuroendocrine Responses to Physostigmine in Alzheimer's Disease. In: Archives of General Psychiatry. 1989 ; Vol. 46, No. 6. pp. 535-540.
@article{d4ce821a50194c8c90971c4efde74577,
title = "Neuroendocrine Responses to Physostigmine in Alzheimer's Disease",
abstract = "To assess central nervous system cholinergic neuroendocrine regulation in Alzheimer's disease (AD), we measured plasma arginine vasopressin, β-endorphin, and epinephrine responses to a cholinergic challenge elicited by intravenous administration of the acetylcholinesterase inhibitor physostigmine (0.0125 mg/kg) in male patients with AD (n =12) and compared their responses with those of age-matched normal control subjects (n =12). Physostigmine promptly increased plasma arginine vasopressin (tenfold), β-endorphin (twofold to threefold) and epinephrine (threefold) levels in elderly control subjects. In contrast, patients with AD showed attenuated responses to physostigmine. When controls and patients with AD who experienced nausea (n = 2 and n = 6, respectively) were excluded, the arginine vasopressin, β-endorphin, and epinephrine responses of patients with AD were significantly less than those of control subjects. These data suggest that the central nervous system cholinergic deterioration of AD results in decreased responsiveness of neuroendocrine systems that are regulated by central cholinergic mechanisms.",
author = "Raskind, {Murray A.} and Peskind, {Elaine R.} and Veith, {Richard C.} and Risse, {Steven C.} and Lampe, {Thomas H.} and Soo Borson and Gail Gumbrecht and Daniel Dorsa",
year = "1989",
doi = "10.1001/archpsyc.1989.01810060057009",
language = "English (US)",
volume = "46",
pages = "535--540",
journal = "JAMA Psychiatry",
issn = "2168-622X",
publisher = "American Medical Association",
number = "6",

}

TY - JOUR

T1 - Neuroendocrine Responses to Physostigmine in Alzheimer's Disease

AU - Raskind, Murray A.

AU - Peskind, Elaine R.

AU - Veith, Richard C.

AU - Risse, Steven C.

AU - Lampe, Thomas H.

AU - Borson, Soo

AU - Gumbrecht, Gail

AU - Dorsa, Daniel

PY - 1989

Y1 - 1989

N2 - To assess central nervous system cholinergic neuroendocrine regulation in Alzheimer's disease (AD), we measured plasma arginine vasopressin, β-endorphin, and epinephrine responses to a cholinergic challenge elicited by intravenous administration of the acetylcholinesterase inhibitor physostigmine (0.0125 mg/kg) in male patients with AD (n =12) and compared their responses with those of age-matched normal control subjects (n =12). Physostigmine promptly increased plasma arginine vasopressin (tenfold), β-endorphin (twofold to threefold) and epinephrine (threefold) levels in elderly control subjects. In contrast, patients with AD showed attenuated responses to physostigmine. When controls and patients with AD who experienced nausea (n = 2 and n = 6, respectively) were excluded, the arginine vasopressin, β-endorphin, and epinephrine responses of patients with AD were significantly less than those of control subjects. These data suggest that the central nervous system cholinergic deterioration of AD results in decreased responsiveness of neuroendocrine systems that are regulated by central cholinergic mechanisms.

AB - To assess central nervous system cholinergic neuroendocrine regulation in Alzheimer's disease (AD), we measured plasma arginine vasopressin, β-endorphin, and epinephrine responses to a cholinergic challenge elicited by intravenous administration of the acetylcholinesterase inhibitor physostigmine (0.0125 mg/kg) in male patients with AD (n =12) and compared their responses with those of age-matched normal control subjects (n =12). Physostigmine promptly increased plasma arginine vasopressin (tenfold), β-endorphin (twofold to threefold) and epinephrine (threefold) levels in elderly control subjects. In contrast, patients with AD showed attenuated responses to physostigmine. When controls and patients with AD who experienced nausea (n = 2 and n = 6, respectively) were excluded, the arginine vasopressin, β-endorphin, and epinephrine responses of patients with AD were significantly less than those of control subjects. These data suggest that the central nervous system cholinergic deterioration of AD results in decreased responsiveness of neuroendocrine systems that are regulated by central cholinergic mechanisms.

UR - http://www.scopus.com/inward/record.url?scp=0024342712&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0024342712&partnerID=8YFLogxK

U2 - 10.1001/archpsyc.1989.01810060057009

DO - 10.1001/archpsyc.1989.01810060057009

M3 - Article

VL - 46

SP - 535

EP - 540

JO - JAMA Psychiatry

JF - JAMA Psychiatry

SN - 2168-622X

IS - 6

ER -